Paraneoplastic Isaacs syndrome leading to diagnosis of small-cell lung cancer P araneoplastic Isaacs syndrome is a rare disorder with distinct clinical and electromyographic characteristics. It is a consequence of neoplastic process that is not directly caused by the tumor itself, but usually mediated by immune response primarily against the tumor and neural tissues are damaged owing to bystander e ect. Paraneoplastic neurologic disorders may precede cancer diagnosis. Here we report the case of 75-year-old woman who presented with numbness, tingling sensation, and weakness of lower extremities, and was diagnosed with Isaacs syndrome and subsequently small-cell lung cancer. Plasmapheresis and treatment of small-cell lung cancer produced signi cant symptoms improvement. We also conduct a complete review of the published case reports and case series of Isaacs syndrome of paraneoplastic etiology (Table) , which usually has good response to carbamazepine and to speci c treatment of underlying neoplasm.
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Case presentation and summary
A 75-year-old woman with a past medical history of hypertension and hyperlipidemia presented to the neurology clinic. Initially she had numbness and tingling sensation of all extremities followed by weakness of the lower extremities that started in the distal parts and progressed proximally. She had also lost the ability to write and was not able to carry out her activities of daily living.
Eight years before presentation, she had been evaluated for peripheral neuropathy that started abruptly on the left side of the body. She had magnetic resonance imaging (MRI) of the brain, which demonstrated chronic small-vessel ischemia with microinfarcts. She subsequently underwent right carotid endarterectomy; however, her paresthesia had progressed and further work-up showed IgM lambda monoclonal gammopathy without IgM elevation. Electromyography (EMG) showed mild sensory axonal neuropathy in addition to a mild left L5 radiculopathy. Her monoclonal gammopathy had resolved on subsequent visit. She had unremarkable colonoscopy a year before presentation. Her home medications included amlodipine, hydrochlorothiazide, omeprazole, aspirin, and metoprolol. She had history of 50 pack-years of smoking and had quit 8 years before presentation.
Physical examination revealed percussion myotonia (delayed relaxation) of the left hand, myotonia of the tongue, inability to release the handgrip, decreased pinprick sensation and proprioception, and decreased strength in the lower extremities. Deep tendon re exes of biceps, triceps, quadriceps, and Achilles were 1+ bilaterally, denoting very slight re ex detected or detected only with reinforcement. Her complete blood count and complete metabolic pro les were within normal range. Serum and urine electrophoresis were negative for monoclonal protein. Vitamin B12 and thyroid-stimulating hormone levels were also normal. A computed-tomography (CT) scan of the brain was normal. An cerebrospinal uid (CSF) analysis showed very mild elevation of protein (51 mg/dL), with 2 nucleated cells/µL (all were lymphocytes). CSF IgG index was 0.46, with no oligoclonal band identi ed. An EMG demonstrated the presence of neuromyotonia and myokymic discharges in the rst dorsal interosseus, foot interossei, tibialis anterior, and vastus lateralis, consistent with Isaacs syndrome. Voltage-gated potassium channel antibody was negative. e patient also had vesicular rash on dermatome C6-7, consistent with varicella zoster reactivation and for which she was started on a course of valacyclovir 1,000 mg tid for 10 days. She was hospitalized for profound weakness such that she was not able to walk or care for herself. Her motor symptoms improved after a week of hospi-talization along with sensory symptoms after initiation of gabapentin with titration up to 1,800 mg a day, and was later changed to pregabalin 150 mg bid due to persistent post-herpetic neuralgia.
A CT scan of the chest, abdomen, and pelvis obtained for malignancy screening demonstrated a 10 x 8 mm right lung nodule with right hilar adenopathy and multiple enlarged mediastinal lymph nodes (Figure 1 ). Bronchoscopy revealed bilateral di use thickening of bronchial mucosa and 2 fungating masses in the trachea. Endobronchial ultrasound with biopsy was done. Pathology revealed small-cell carcinoma from the right level 4 lymph node aspiration specimen. MRI of thoracic spine also showed complete marrow replacement of T9 vertebral body, but MRI of the brain was negative for metastasis ( Figure 2 ). She was diagnosed with extensive stage small-cell carcinoma. Chemotherapy with carboplatin (AUC 3) and etoposide (100 mg/m 2 ) was started. She was in the hospital for 7 days and released when she had a marked improvement in strength and was able to walk some and do some self-care.
A month after discharge, she experienced worsening of her weakness and paresthesia. Screening for anti-neuronal nuclear antibodies and Purkinje cell cytoplasmic antibody were negative. Plasma exchange was initiated and resulted in signi cant improvement in her strength; however, the e ect lasted about 4 weeks and plasma exchange was repeated. Carbamazepine 100 mg bid was initiated to help relieve her neurological symptoms; but she did not tolerate the medication due to presyncope symptoms.
She completed 4 cycles of carboplatin and etoposide, but the treatment was complicated by her multiple hospitalizations with fever and abdominal pain. Subsequent chest CT imaging showed good response to the carboplatin and etoposide regimen with signi cant improvement in myotonia and, to a lesser extent, paresthesia. e disease recurred after 4 months after the completion of her last cycle of chemotherapy, as evidenced by a CT scan and con rmed with transbronchial biopsy. Second-line chemotherapy with topotecan was discussed but deemed too toxic. She opted to pursue palliative radiation to the chest. Brain metastasis was noted just before the initiation of radiation treatment. She received thoracic and whole brain radiation (3950 cGy/16 fractions and 3000 cGy/10 fractions, respectively).
e patient subsequently developed multilobar pneumonia and died of hypoxic respiratory distress and septic shock, 7 months after diagnosis of small-cell lung cancer.
Discussion
Hyam Isaacs, a South African neurologist, described 2 cases with a syndrome of continuous muscle ber activity. 1 Needle EMG of both patients showed a similar pattern of constant rapid dysrhythmic discharge of independent muscle bers that worsened with voluntary movement. Phenytoin was found to relieve the symptoms and led to signi cant improvement of muscle power of both cases, suggesting that the defect may be at the peripheral nerve cell membrane. e syndrome was sometimes de ned as acquired neuromyotonia (continuous muscle activity arising from peripheral nerve). 2 However, the mechanism behind the pathogenesis was not elucidated until it was suggested by Bostock and Baker 3 that human motor axon also possesses a slow potassium channel that is directly related to threshold electrotonus, which might explain neuromyotonia. Several associations of neuromyotonia 
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Continued from previous page with autoimmune conditions such as myasthenia gravis and celiac disease were reported 4 . Sinha 5 reported a case of neuromyotonia who had signi cant improvement in symptoms with plasma exchange. Puri ed IgG of the patient was passively transferred to mice, producing resistance to d-tubocurarine at the neuromuscular junction, along with observed decrease in mice activity. Further cellular electrophysiologic study of mice motor neuron preparation indicated increased presynaptic nerve-terminal membrane excitability, which is known to be related to slow potassium channel. Voltage-gated potassium channel (VGKC) is usually concentrated around the paranodal and terminal region of myelinated axon. 6 Hart and colleagues demonstrated that patients with acquired neuromyotonia exhibit autoantibodies against various types of VGKCs, establishing the pathophysiologic basis of the disease. 7 Autoantibodies to VGKC are not only implicated in peripheral nerve diseases as in Isaacs syndrome, but also in central nervous system disease such as limbic encephalitis. Patients with Morvan syndrome develop both central (mostly autonomic) and peripheral nervous system pathology from antibody to VGKC and tend to have greater proportion of paraneoplastic etiology. 8 Isaacs syndrome is rare with prevalence expected to be less than 1 in 100,000. ere is male predominance in this syndrome, with the male:female ratio at around 1.8:1 in 2 case series, 9, 10 and as extreme as 19:1 in a series. 11 It is associated with both autoimmune disorders and can be nonimmune-mediated. 4 e reported autoimmune disorders include paraneoplastic syndrome, myasthenia gravis, diabetes mellitus, chronic in ammatory demyelinating neuropathy, Guillain-Barré syndrome, Addison disease, celiac disease, pernicious anemia, hypothyroidism, rheumatoid arthritis, systemic lupus erythematosus, and so on. Association with possible non-immune mediated conditions includes toxins (insecticide, alcohol, venom) and potassium-channel gene mutations.
Our patient presented with weakness and paresthesia, which are not typical presentation of the disease. 4 Most patients with Isaacs syndrome usually complain of muscle cramps and twitching. 2 Distal sensory loss occurs in only minority of the patients. Physical examination of our patient revealed relaxation myotonia, which is seen in around one third of patients with this syndrome (pseudomyotonia). e patient's EMG nding was consistent with neuromyotonic and myokymic discharge, both of which are prominent features of Isaacs syndrome. Neuromyotonic discharge is caused by hyperexcitability of single motor axon of peripheral nerve and has speci c characteristics on EMG described as doublet, triplet, or short bursts of high intraburst frequency (30-300 Hz) single motor unit (or partial motor unit) discharge, producing a short, highpitched "ping" sound from the EMG machine. 12 Myokymic discharge is the regular or irregular discharge of groups of motor units causing ickering of the muscle. EMG can differentiate myokymia from fasciculation and myoclonus by its characteristics of lower frequency (2-60 Hz) doublets, triplets, or multiplets in short rhythmic burst of motor unit action potential, followed by a silence and recurrence of the burst at regular intervals. As evident in many other paraneoplastic syndromes, Isaacs syndrome usually improves after speci c treatment of an underlying malignancy. Plasma exchange was also shown to signi cantly improve our patient's muscle weakness even though the e ect was not long lasting. is treatment strategy is supported by case reports 13, 14 and a practice guideline. 15 Plasma exchange usually results in a decrease in anti-VGKC antibody titer and clinical improvement that lasts around 6 weeks. e role of immunosuppressive agents is not well established.
Symptomatic treatment with phenytoin, carbamazepine, lamotrigine, and valproate or combinations of these agents has been reported to improve symptoms. 15 We reviewed 49 cases of paraneoplastic Isaacs syndrome published in case reports or case series in English or Spanish. Of the 30 patients with available data, the age range is 29-76 years (median, 59 years). Of 31 patients with available gender data, 23 of them are men (2.9:1, male:female ratio). Twenty-six patients had VGKC antibody tested, and 16 (61.5%) were positive. e clinical implication of positive antibody is di cult to determine owing to the lack of data; however, from case reports with reported outcomes, VGKC antibody positivity does not seem to a ect the response to treatment or clinical outcome. e most common neoplastic process associated with Isaacs syndrome is thymoma (25 of 49 patients, 51.0%), followed by small-cell carcinoma (6 patients, 12.2%). Other reported neoplastic processes include bronchogenic carcinoma, renal cell carcinoma, bladder carcinoma, ovarian carcinoma, oncocytic tumor of the thyroid, spinal cord hemangioblastoma, plasmacytoma, light-chain (AL) amyloidosis, Hodgkin lymphoma, lymphoplasmacytic lymphoma, and essential thrombocythemia. Most of the patients responded to treatment with carbamazepine and had complete neurological resolution after speci c treatment of the underlying neoplasms. Plasma exchange was also shown to improve neurological symptoms.
Conclusion
Paraneoplastic Isaacs syndrome is a rare neurological disorder that can present with muscle cramping, twitching, weakness, and sensory symptoms. is syndrome is diagnosed by speci c EMG patterns de ned as neuromyotonic and myokymic discharge. Patients usually respond to treatment with carbamazepine or phenytoin, and typically have complete neurologic resolution after speci c treatment of neoplastic process.
